Interest in Omicron-related stocks is high.
While there is a lot of interest in the meaning, vaccine, and mortality rate of the Omicron mutation virus, the World Health Organization (WHO) is expressing the position that more time is needed to understand the ‘Omicron mutation’.
According to Reuters, the WHO said in a statement issued on the 28th (local time) that the contagiousness and severe risk of Omicron have not yet been clearly identified.
Preliminary data from the WHO predicts that hospitalization rates in South Africa are rising, but that this may be due to an overall increase in the number of infections rather than Omicron.
At the same time, there is currently no information to suggest that the symptoms of Omicron are different from other mutations.
However, according to preliminary data, it is analyzed that there is a possibility that the risk of re-infection due to Omicron may increase even in those who have been cured of COVID-19.
The WHO also added that the gene amplification PCR test can diagnose Omicron infection, but it is currently under study whether the rapid antigen test will continue to be effective.
On the other hand, domestic related stocks of Omicron include Seegene, Labgenomics, Humasys, SD Biosensor, Access Bio, PHC, Nano Entech, Syswork, Sugentech, Body Tech Med, and Gene System.
